Juniper Pharma (JNP) Posts Q4 Loss of $0.19/Share as Revenue Rise to $7.6M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Juniper Pharmaceuticals Reports Fourth Quarter and Full-Year 2015 Financial Results
March 10, 2016 6:17 AM ESTBOSTON, March 10, 2016 /PRNewswire/ --Â Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) ("Juniper" or the "Company"), a women's health therapeutics company, today announced financial results for the three- and twelve-month periods ended December 31, 2015.Â
"2015 was a transformative year for Juniper, with strong performance in every aspect of our business," stated Frank Condella, Chief Executive Officer. "We made significant progress in R&D, advancing COL-1077 10% lidocaine vaginal gel into the clinic as a promising anesthetic for pain associated with minimally-invasive gynecologic procedures. We look forward to... More
